Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.

J Alfred Witjes,Juan Morote,Erik B Cornel,Georgios Gakis,F Johannes P van Valenberg,Fernando Lozano,Itay A Sternberg,Ellen Willemsen, Miriam L Hegemann,Yossi Paitan,Ilan Leibovitch

European Urology Oncology（2018）

引用 100|浏览18

暂无评分

摘要

Bladder EpiCheck is a methylation-based urine assay for detection of bladder cancer. It might serve as a rule-out test for intermediate- and high-risk non–muscle-invasive bladder cancer. Thus, the test could avoid unnecessary procedures, reducing both the financial and patient burden of repeat cystoscopies.

查看译文

关键词

Detection,Follow up,Negative predictive value,Non–muscle-invasive bladder cancer,Surveillance,Urinary biomarker

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要